ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Thyroid Disease and Breast Cancer Risk in the Sister Study.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThyroid disease and its treatments are suspected risk factors for breast cancer, attributed primarily to alterations in thyroid hormone-related metabolism. Prior literature is inconsistent, in part, due to small sample sizes. We, therefore, assessed the effects of hyper- and hypothyroidism on incident breast cancer in a large cohort of US women.
methodsData are from the Sister Study, a prospective cohort of 50,884 US women with no breast cancer history at enrollment (2003-2009; ages 35-74 years) and follow-up through September 2021. We used time-varying Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between self-reported thyroid diseases and treatments and incident breast cancer.
resultsOf 45,783 eligible participants, 11,567 reported thyroid disease at baseline and over follow-up (hyperthyroidism: n = 1,710; hypothyroidism: n = 9,857), and 3,897 participants subsequently developed breast cancer. Breast cancer HR was 1.15 (95% CI, 0.95-1.39) for those with hyperthyroidism and 0.93 (95% CI, 0.85-1.01) for those with hypothyroidism, compared with no thyroid disease, with similar patterns observed across racial and ethnic groups. Hyperthyroidism was associated with greater premenopausal breast cancer hazard (HR = 1.85; 95% CI, 1.11-3.07) and differed from breast cancer hazard for hypothyroidism, which seemed reduced (HR = 0.75; 95% CI, 0.54-1.05) but did not reach statistical significance (Pheterogeneity = 0.06). Breast cancer hazards were higher, albeit not statistically significant, for those treated for hyperthyroidism but not hypothyroidism.
conclusionsWomen diagnosed with hyperthyroidism or receiving related treatment may have an elevated breast cancer risk, particularly for premenopausal breast cancer. IMPACT: Although more research is needed, premenopausal women treated for hyperthyroidism may benefit from enhanced breast cancer screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.